Combining drugs and radiotherapy: From the bench to the bedside

Current Opinion in Neurology

Volumn 22, Issue 6, 2009, Pages 625-632

  Palanichamy, Kamalakannan ^a   Chakravarti, Arnab ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Chemoradiotherapy; Clinical trials; Correlative studies; Glioblastoma; Therapeutic targets

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; AGO 14699; ATR PROTEIN; BEVACIZUMAB; BORTEZOMIB; CARMUSTINE; CILENGITIDE; DEOXYGLUCOSE; ERLOTINIB; EVEROLIMUS; GEMCITABINE; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1; INO 1001; IRINOTECAN; LACTATE DEHYDROGENASE; LOMEGUATRIB; LONIDAMINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PHOSPHATIDYLINOSITOL 3 KINASE; RADIOSENSITIZING AGENT; TEMOZOLOMIDE; TRC 102; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNTRANSLATED RNA; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VORINOSTAT;

ALOPECIA; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APHTHOUS STOMATITIS; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; CLINICAL TRIAL; DNA METHYLATION; ERYTHEMA; EXCISION REPAIR; GLIOBLASTOMA; HUMAN; MISMATCH REPAIR; OUTCOME ASSESSMENT; PROGNOSIS; REVIEW; STOMATITIS; TUMOR ESCAPE; TUMOR VASCULARIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GLIOBLASTOMA; HUMANS; RADIOTHERAPY;

EID: 74049114949     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283327d33     Document Type: Review

References (41)

1. Vredenburgh AD, Reardon DA, Peters K, et al. Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM) [ASCO Annual Meeting Proceedings]. J Clin Oncol 2009; 27:2015.
2. Stupp R, Mason WP, van den Bent MJ, etal. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
3. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007; 25:4127-4136.
4. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.
5. Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related 'self-renewal' signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008; 26:3015-3024.
6. Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006; 12:4738-4746.
7. Nieder C, Mehta MP, Jalali R. Combined radio-and chemotherapy of brain tumours in adult patients. Clin Oncol (R Coll Radiol) 2009; 21:515-524.
8. Pouratian N, Crowley RW, Sherman JH, etal. Gamma knife radiosurgery after radiation therapy as an adjunctive treatment for glioblastoma. J Neurooncol 2009; 94:409-418.
9. Stupp R, Hegi ME, Mason WP, etal. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459-466.
10. KubicekGJ, Werner-WasikM, Machtay M, etal. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2009; 74:433-439.
11. Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009; 27:579-584.
12. Blumenthal DT, Wade M, Rankin CJ, et al. MGMT methylation in newly-diagnosed glioblastoma multiforme (GBM): from the S0001 phase III study of radiation therapy (RT) and O(6)-benzylguanine, (O(6)BG) plus BCNU versus RTand BCNU alone for newly diagnosed GBM. J Clin Oncol 2006; 24:1512.
13. Russo AL, Kwon HC, Burgan WE, et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 2009; 15:607-612.
14. Sigmond J, Honeywell RJ, PostmaTJ,et al. Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. Ann Oncol 2009; 20:182-187.
15. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444:633-637.
16. Di Micco R, Fumagalli M, Cicalese A, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444:638-642.
17. Singh D, Banerji AK, Dwarakanath BS, et al. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 2005; 181:507-514.
18. Wu H, Zhu H, Liu DX, et al. Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy. Cancer Res 2009; 69:2453-2460.
19. Lena A, Rechichi M, Salvetti A, et al. Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells. J Transl Med 2009; 7:13.
20. Oudard S, Carpentier A, Banu E, et al. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol 2003; 63:81-86.
21. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3:24-40.
22. Reardon DA, Desjardins A, Rich JN, Vredenburgh JJ. The emerging role of antiangiogenic therapy for malignant glioma. Curr Treat Options Oncol 2008; 9:1-22.
23. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009; 72:1217-1222.
24. Mishima K, Mazar AP, Gown A, etal. A peptide derived from the nonreceptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci USA 2000; 97:8484-8489.
25. MaurerGD,Tritschler I, Adams B, etal. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol 2009 [Epub ahead of print]. doi: 10.1215/ 15228517-2009-2012
26. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26:5610-5617.
27. Reardon DA, Nabors LB, Stupp R, Mikkelsen T. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 2008; 17:1225-1235.
28. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-1812.
29. Yan H, Parsons DW, Jin G, etal. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765-773.
30. Cancer Genome Atlas Research Network. Comprehensive genomic charac-terization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061-1068.
31. Yadav AK, Renfrow JJ, Scholtens DM, et al. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glio-blastomas. JAMA 2009; 302:276-289.
32. Pelloski CE, Lin E, Zhang L, et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 2006; 12:3935-3941.
33. Chinnaiyan P, Wang M, Rojiani AM, et al. The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group. Radiat Oncol 2008; 3:32.
34. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to antiepidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phospho-inositide 3-kinase signaling. Cancer Res 2002; 62:200-207.
35. Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002; 20:1063-1068.
36. Chakravarti A, Seiferheld W, Tu X, et al. Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005; 62:318-327.
37. Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005; 62:309-317.
38. Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 2004; 22:1926-1933.
39. Sie M, Wagemakers M, Molema G, et al. The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme. J Neu-rosurg 2009; 110:147-155.
40. Chakravarti A, Wang M, Mischel P, et al. An update on correlative molecular Endpoints from RTOG 0211: phase I/II study of gefitinib plus radiation for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys 2008; 72:S9-S10.
41. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012-2024.